Treatment C(AD-236A+AD-236B)

Phase 1

AAddpharma Inc.

Treatment C(AD-236A+AD-236B) is one of 19 therapeutic programs targeting Hyperlipidemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HyperlipidemiaNot yet recruiting

HyperlipidemiaPhase 1

Not yet recruiting

Competition

Competitive Landscape

25 competitors in Hyperlipidemia

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

7 2

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

8 3

Leqvio

Niacor

Mounjaro

Ozempic

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 8

Livalo

MMedicure

Approved

1 9

Topamax

WWim Janssens

Approved

—10

Januvia

ZZydus Therapeutics Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Not yet recruiting

Hyperlipidemia

NCT07730567

Clinical

Trials by Indication[1]

Hyperlipidemia1 trial

A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B in Healthy Adult Volunteers

Not yet recruiting·AAddpharma Inc.·Phase 1·NCT07730567·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Treatment C(AD-236A+AD-236B). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Treatment C(AD-236A+AD-236B). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Addpharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AAddpharma Inc.

Treatment C(AD-236A+AD-236B)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Hyperlipidemia1 trial

References

Drug Info

Quick Facts

Related News